These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1736847)

  • 1. Protein redistribution diet remains effective in patients with fluctuating parkinsonism.
    Karstaedt PJ; Pincus JH
    Arch Neurol; 1992 Feb; 49(2):149-51. PubMed ID: 1736847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
    Karstaedt PJ; Pincus JH; Coughlin SS
    Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein redistribution diet and antiparkinsonian response to levodopa.
    Bracco F; Malesani R; Saladini M; Battistin L
    Eur Neurol; 1991; 31(2):68-71. PubMed ID: 2044618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
    J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
    Carter JH; Nutt JG; Woodward WR; Hatcher LF; Trotman TL
    Neurology; 1989 Apr; 39(4):552-6. PubMed ID: 2648188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
    Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
    Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary method for reducing fluctuations in Parkinson's disease.
    Pincus JH; Barry KM
    Yale J Biol Med; 1987; 60(2):133-7. PubMed ID: 3577210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
    Datieva VK; Makotrova TA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):13-9. PubMed ID: 23250605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.